Lynx1 Capital Management LP

Lynx1 Capital Management LP reported 31 holdings worth US$646M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Lynx1 Capital Management LP reported 31 holdings worth US$646M as of Sep 30, 2026. Largest: Cullinan Therapeutics, Inc., Stoke Therapeutics, Inc. and C4 Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
31
Value as reported
US$646M

The filing in full

CompanySharesValue as reported% of portfolio
Cullinan Therapeutics, Inc.8.96MUS$138M21.3%
Stoke Therapeutics, Inc.3.9MUS$101M15.7%
C4 Therapeutics, Inc.7.53MUS$25.1M3.9%
Precision BioSciences, Inc.2.76MUS$17.3M2.7%
Agios Pharmaceuticals, Inc.473KUS$15.7M2.4%
Korro Bio, Inc.1.54MUS$15.3M2.4%
Neuphoria Therapeutics Inc.875KUS$3.12M0.48%
Passage Bio, Inc.674KUS$3.03M0.47%
TScan Therapeutics, Inc.8.02MUS$2.52M0.39%
Kazia Therapeutics Ltd226KUS$2.17M0.34%
Pliant Therapeutics, Inc.1.8MUS$1.94M0.30%
Entrada Therapeutics, Inc.279KUS$1.77M0.27%
Surrozen, Inc.20,000US$644K0.10%
Werewolf Therapeutics, Inc.658KUS$607K0.09%
Xencor, Inc.18,194US$454K0.07%
Immunocore Holdings plc14,300US$433K0.07%
Dyne Therapeutics, Inc.25,000US$403K0.06%
Traws Pharma, Inc.559KUS$332K0.05%
Denali Therapeutics Inc.11,658US$241K0.04%
Absci Corporation21,245US$229K0.04%
Foghorn Therapeutics Inc.61,588US$220K0.03%
Avalo Therapeutics, Inc.10,100US$155K0.02%
Prime Medicine, Inc.45,000US$137K0.02%
Bolt Biotherapeutics, Inc.30,800US$113K0.02%
Eupraxia Pharmaceuticals, Inc.10,000US$91,0000.01%
Nuvation Bio Inc.16,029US$89,7620.01%
Inhibikase Therapeutics, Inc.20,000US$1,201<0.01%
CG Oncology, Inc.0US$00.00%
VYNE Therapeutics Inc.0US$00.00%

Source

Download original · View original at SEC

Related